Last quarter I was sitting with a founder — [redacted bootstrapped deep-tech CEO] — and she pulled out a folder of patents her team had filed over the previous four years. Eighteen granted, another twelve pending. She looked at me and said, "We have spent close to half a million on these. What are they actually doing for the business?" The answer at the time was nothing. They were sitting in a portfolio, generating renewal fees, attached to no revenue line.
That conversation is the one I have most often with technically deep founders. They have spent the money to build the IP. They have not spent the time to figure out how the IP creates cash. And in most cases, they are not even aware that there are six distinct routes to turn dormant intellectual property into measurable value.
This is the framework I walk founders through. It works for patents, but the same logic applies to trade secrets, proprietary datasets, and the kind of process know-how that lives in a small number of senior heads.
What IP monetisation actually means
IP monetisation is the work of converting patents, trade secrets, and proprietary data into measurable revenue, defensibility, or strategic optionality. It is not one thing. It is a menu of routes, and the right route depends on your business model, your competitive position, and your tolerance for the operational complexity each route brings.
Most founders think IP monetisation means licensing. Licensing is one of six routes. The other five are usually better fits for early-stage companies, and several of them are happening already inside the business without anyone tracking them.
Route one: product premium
This is the route every founder is using whether they realise it or not. Your product commands a higher price, or wins more customers, because of the IP embedded in it. The patent is not directly generating cash — the product is. But the product would not command its margin without the technical defensibility behind it.
The reason this route is underrated is that it is invisible in most P&Ls. The IP is not a line item. It shows up as gross margin, win rate, and pricing power. Founders who understand this can articulate the IP's contribution to investors and acquirers in concrete terms — "our patent on X is what lets us hold pricing twenty percent above competitors" — instead of vaguely referencing a portfolio.
If you are an operating company selling a product, this is almost always your dominant monetisation route. The work is making it visible and defensible in the diligence pack.
Route two: licensing
Licensing is the route founders ask about first and the one most of them should pursue last. The model is straightforward — you grant another company the right to use your IP in exchange for a fee, royalty, or both. Done well, it is high-margin recurring revenue. Done badly, it consumes operational bandwidth and creates competitors who use your own technology against you.
The companies that license well usually have one of three things in place. A specific, well-bounded patent that covers a single technical capability that other companies want to embed. A clearly defined geographic or vertical segmentation, so the licensee operates in markets the licensor will not serve directly. Or a patent that has matured past the point where the licensor is still actively building on it.
Early-stage operating companies rarely have any of those. The IP is still core to the product, the segmentation is fuzzy, and the team is still iterating. Licensing in that context tends to leak the technical edge to a future competitor for a small upfront cheque.
I tell founders to think about licensing when their IP portfolio has matured past the part of the market they actually want to serve. Until then, route one — capturing the premium through your own product — is almost always the better economics.
Route three: cross-licensing
Cross-licensing is licensing with a barter mechanism. You grant another company access to your IP, they grant you access to theirs, no money changes hands. This is the route that runs quietly inside almost every mature technology sector — semiconductors, telecoms, automotive — and it is starting to matter in AI.
The use case is freedom to operate. You may have built a product that touches a dozen patents owned by competitors. Without cross-licensing arrangements, every product release creates litigation exposure. With them, you trade access to your patents for access to theirs, and everyone keeps shipping.
For an early-stage company, cross-licensing is rarely the starting move. You usually need a portfolio of meaningful patents before larger players are willing to negotiate. But it becomes increasingly relevant as a company grows, and founders who anticipate it tend to file with cross-licensing in mind — building portfolios that touch the same standards or technical areas the larger players care about.
Route four: defensive publication
This one is counterintuitive. Defensive publication is monetisation in the sense that it protects future revenue, but it does so by deliberately not patenting the invention. You publish the technical details, place them in the public domain, and prevent any competitor from later patenting the same idea and blocking your use of it.
The economics are clean. Patents are expensive — often £40,000 to £80,000 in lifetime cost per granted family. Defensive publication costs almost nothing. For inventions that you do not plan to license out, that are not core to your competitive moat, and that you simply need to keep open for your own use, the publication route is materially cheaper than filing.
Most founders use this badly. They patent everything, including inventions they will never license, will never enforce, and could have published for the cost of a blog post. I run portfolio reviews where the recommendation, more often than founders expect, is to drop a third of the filings and switch them to defensive publication. The portfolio gets cheaper. The freedom to operate stays intact.
Route five: portfolio sale or spin-out
This is where dormant IP becomes cash. You sell the patents, or a defined sub-portfolio, to a buyer who has a use for them you do not. Buyers are typically operating companies wanting freedom to operate, NPEs (non-practising entities) running licensing programmes, or larger players acquiring the IP as part of a broader portfolio play.
For early-stage companies the more common version is a spin-out — packaging a sub-portfolio of patents that is no longer core to the main business into a separate entity, and either selling it or running it as a licensing vehicle. I have seen this work cleanly when the parent company is moving up-market and the spun-out IP covers down-market applications. The parent keeps focus, the spin-out generates licensing revenue, and the patents stop being a sunk cost.
Distressed-IP acquisition is the inverse of this route. When an operating company shuts down or pivots, its IP often gets sold for pennies. There is real opportunity for founders and investors who know how to value those portfolios — but that is a different conversation from monetising your own IP.
Route six: strategic value at exit
The sixth route is the one that matters most for venture-backed companies, and it is the hardest to model in advance. Your IP is valued by an acquirer as part of the overall transaction price. The patents do not generate revenue directly — they generate exit multiple.
The mechanics of this are real. Acquirers underwrite acquisitions partly on the technical defensibility of the target. A company with a coherent patent strategy, well-drafted claims, and clear ownership tends to clear diligence faster, justify a higher multiple, and survive the legal review without surprises. A company with a messy portfolio — half-abandoned filings, unclear inventorship, gaps where there should be coverage — usually sees the acquirer adjust the price down or ask for warranties.
The work for founders is not waiting until the M&A process to think about this. It is building the portfolio with exit in mind from the early years. That means filing on the things that matter, abandoning the things that do not, keeping inventorship clean, and maintaining a portfolio map that an acquirer's IP team can read in an afternoon.
I run pre-M&A IP audits for founders six to twelve months before they expect to start exit conversations. Most of the work that comes out of those audits is not about generating new IP — it is about cleaning up what already exists so the diligence pack does not destroy the negotiating position.
Which route fits your business
The routes are not equally weighted. For most early-stage operating companies, route one — capturing the premium in your own product — is dominant. Routes three and four are housekeeping. Route five only becomes interesting when the portfolio has matured past the core business. Route two is usually premature. Route six is what the whole portfolio is being optimised for, even when no one is talking about it.
The work I do with founders is figuring out, given their specific business model and IP position, which routes to lean into and which to ignore. That is the difference between a portfolio that supports the business and a portfolio that drains it.
The questions I get asked most
The first one is always: when should I start thinking about monetisation? My answer is the day you file your first patent. If you cannot articulate which of the six routes the filing is feeding, the filing is probably premature.
The second is whether you can monetise IP without licensing it out. Yes, in five of the six routes you do not license anything to anyone. The premium captured in your product, the freedom to operate created by defensive publication, the exit multiple built over years — none of those involve licensing. Licensing is the most visible route, not the most common.
The third is whether trade secrets and proprietary data fit the same framework. They do, with adjustments. The same six routes apply, but the legal mechanics differ. Trade secrets cannot be defensively published — that destroys them. Data cannot be cross-licensed in the same way patents can. The framework is the same; the instruments under each route shift.
If you want to walk through which routes fit your specific portfolio and business model, that is what we do at Beyond Elevation. I run an IP strategy engagement that maps the portfolio to the routes and tells you, in plain English, where the value is and where the spend is wasted.
By Hayat Amin — founder, Beyond Elevation. I advise pre-seed through Series B founders on patent strategy, IP monetisation, and turning research into defensible value.